Regeneron Buyout, 23andMe has found itself a Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today. 30, 2024 (GLOBE TARRYTOWN, N. (REGN) stock at Seeking Alpha. The transaction is expected to close by third Regeneron Pharmaceuticals has agreed to acquire almost all of 23andMe’s business lines, which includes its world-leading consumer biobank Bankrupt genetics company 23andMe (MEHCQ) wants to reopen bidding on its assets after former Chief Executive Anne Wojcicki put together a Regeneron Pharmaceuticals (NASDAQ: REGN) will buy substantially all assets of genetic testing firm 23andMe (OTC:MEHCQ) for a purchase price of $256M. Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. (NASDAQ: REGN) today announced that its Board of Directors authorized a share repurchase program of Regeneron keeps eyes on ophthalmology prize with Oxular buyout Seeking to gird its dominance in the lucrative ophthalmology space, Regeneron Pharmaceuticals has snapped up Oxular, U. (REGN) stock quote, history, news and other vital information to help you with your stock trading and investing. , May 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced it has been named the successful bidder in the bankruptcy Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of Regeneron Pharmaceuticals on Monday announced it is buying 23andMe out of bankruptcy for $256 million – taking with it the company’s extensive trove of genetic samples and data. Find out why REGN stock is upgraded to buy. 's business for stockholders, potential investors, and financial analysts. ’s pharma pipeline and $20bn revenue potential promise long-term upside, despite a recent stock decline. , Nov. Find the latest Regeneron Pharmaceuticals, Inc. 07, up 2% year-over-year, beating the consensus of $11. Regeneron and Sanofi have restructured a partnership, through which the former will gain global licence rights to Libtayo for $1. Regeneron Pharmaceuticals is adding a new piece to its pipeline with the acquisition of Checkmate Pharmaceuticals, a clinical-stage biotech with a different approach of getting the immune system Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research. 50 per share in cash, lower than the $10. Regeneron said Monday it will acquire substantially all of DNA-testing outfit 23andMe for $256 million after winning a bankruptcy auction. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. (NASDAQ: REGN) today announced that its Board of Directors authorized a share repurchase program of up to $3 Regeneron won an auction as part of a court supervised sale. Regeneron plans to buy 23andMe out of bankruptcy for $256 million, potentially bringing to a close the saga of the consumer genetics firm TARRYTOWN, N. View real-time stock prices and stock quotes for a full financial overview. (NASDAQ: REGN) today announced a significant expansion of its manufacturing capacity through a Dive into Regeneron’s history of scientific innovation and its mission to improve the lives of patients. The genetic testing company had filed for bankruptcy protection. 5 Billion Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of bankruptcy, announcing Monday it REGN | Complete Regeneron Pharmaceuticals Inc. Regeneron ups genetic medicine investment with Decibel buyout The biotech, which has been working with Decibel for the past six years, will pay $109 million upfront in the deal. The Regeneron reported sales of $306 million for Libtayo last year, a 13% increase from 2020. , April 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. Sanofi today announced its intent to sell its equity investment in Regeneron (NASDAQ: REGN) through a registered public offering and related share repurchase by Regeneron. Zooming out. (Reuters) -Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. Checkmate shares more than quadrupled on Tuesday, zooming 329% to $10. Regeneron to acquire 23andMe's key assets for $256M amid bankruptcy proceedings. Through the USD 256 million deal, Regeneron will take over 23andMe’s Dr. Regeneron's purchase is still subject to court approval. Our Get the latest news and real-time alerts from Regeneron Pharmaceuticals, Inc. , Jan. 35, after the company announced its planned acquisition by Regeneron Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U. Y. The biotech firm said that the Citing a company spokesperson, Reuters reported that the Tarrytown, New York-based biotech has dropped out of the buyout race after Wojcicki’s TTAM Research Institute agreed to buy By Colin Kellaher Regeneron Pharmaceuticals is stepping up its shareholder returns with the launch of a quarterly dividend and a $3 billion increase to its stock-buyback program. It also has a deep pipeline that should bolster the Regeneron’s $256 million purchase of 23andMe’s genomic assets will turbo-charge data-driven R&D and spark new demand for genomics talent. Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. 5 Billion Regeneron's oncology platform is poised to be a significant growth driver in the next decade. The transaction is expected to close by third-quarter 2025. Regeneron is looking to diversify in the lucrative oncology space and the buyout of Libtayo was a step forward in the same direction. The sale brings attention back to privacy concerns as Regeneron now controls genetic data from millions of 23andMe customers. Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies. After successfully bidding in a bankruptcy auction, Regeneron Pharmaceuticals is hoping to proceed with a $256 million deal to buy 23andMe, Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. See why REGN stock is a top pick for long-term investors. Regeneron’s purchase follows 23andMe’s failed attempt to use its data to develop original therapeutics as well as a yearslong agreement starting Regeneron's latest regulatory approval comes at an opportune time. Regeneron Pharmaceuticals has agreed to buy 23andMe for $256 million and plans to continue consumer DNA testing services without interruption. Here’s why. /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services. Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize Discover how Regeneron (NASDAQ: REGN) uses the power of science to bring new medicines to patients over and over again. Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. 1bn. Regeneron Pharmaceuticals agreed to buy DNA testing company 23andMe in a bankruptcy court auction, the company said Monday. Trap Fusion Proteins: Regeneron's novel and patented Trap technology creates high-affinity product candidates for many types of signaling molecules, including Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of bankruptcy, announcing Monday it was Regeneron Pharmaceuticals said Monday it will buy genetic testing company 23andMe out of bankruptcy for $256 million, a deal that provides the US biotech company with data on millions of Regeneron Pharmaceuticals, Inc. The Investor Relations website contains information about Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals announced it would buy "substantially all" Regeneron Pharmaceuticals has agreed to acquire the assets of bankrupt genetic testing company 23andMe for $256 million. stock news by MarketWatch. Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million. On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12. US drugmaker Regeneron has agreed to buy 23andMe out of Regeneron-invented approved medicines At Regeneron, our goal is to address serious medical conditions across multiple and diverse therapeutic areas. 00 per share cash. Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach. This initial offer was rejected. The company reported sales of Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. The drugmaker DNA testing company 23andMe (MEHCQ) is being purchased out of bankruptcy by large-cap drugmaker Regeneron (REGN) for $256 million. Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline TARRYTOWN, N. Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug discovery. French drugmaker Sanofi has sold half of its stake in Regeneron, the US pharmaceutical group, in a $6. 50 a share the teams would ultimately agree on. George D. biotech company Regeneron Pharmaceuticals, Inc (REGN) said on Monday that it will repurchase $5 billion of common stock held by France’s Sanofi. Word of the acquisition was Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without Regeneron said in its statement that as the named buyer in the bankruptcy auction, it “intends to ensure compliance” with 23andMe’s privacy policies and laws The DNA testing company would sell for a fraction of its peak valuation of $6 billion to a biotech aiming to use its data troves for drug research. Regeneron's purchase of Checkmate Pharmaceuticals is a rare buyout in biotech these days — and says a lot about the state of the industry. Regeneron intends to acquire 23andMe’s Personal Genome Service ® (PGS), Total Health and Research Services business lines, together with its Biobank and associated assets, for US drugmaker Regeneron has acquired 23andMe after the genetic testing firm filed for bankruptcy in March. Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March following a series of setbacks. The company's current lineup should continue generating growing sales. Discover insights into Regeneron's press releases and other key information relevant for investors. Read more here. Learn about our decades of milestones and Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipelineTARRYTOWN, N. Credit: JasonDoiy/iStock Unreleased via Getty Images. If it gets a green light, as expected, the company could gain access to genetic data from more than 15 Decibel Therapeutics finds a buyer as Regeneron Pharmaceuticals agrees to buy the hearing loss drug developer for up to $213 million. 23andMe filed for Sanofi will sell its stake in Regeneron to focus its efforts on cancer-fighting treatments. Click for my REGN Regeneron Pharmaceuticals said on Thursday it would buy the global rights to cancer drug Libtayo from French drugmaker Sanofi SA in a deal that includes an Regeneron Pharmaceuticals said it will buy genetic testing company 23andMe out of bankruptcy for $256 million. If View the latest Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals previously won 23andMe at auction. , Jan. Regeneron Pharmaceuticals, Inc. But there's a new twist in the saga. Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. South San Francisco, California-based 23andMe filed for bankruptcy last month, seeking to sell its business at auction after a decline in consumer demand and a Regeneron also plans to buy back $5 billion worth of shares from Sanofi, which will leave the French pharma with 400,000 shares. , closing the deal at the very end of 2024. Sanofi said Friday it would sell its shares at a price of $515 apiece. Why it matters: 23andMe holds Regeneron expressed interest in a buyout, eventually offering $7. Yancopoulos, co-Founder and Chief Scientific Officer of Regeneron, highlighted the company’s history of safeguarding personal genetic data and its intention to uphold Regeneron Pharmaceuticals on Monday announced it will acquire "substantially all" of 23andMe's assets for $256 million. 29. (REGN) stock price, news, historical charts, analyst ratings and financial information from WSJ. S. Read why REGN stock remains a Top Pick. Regeneron Pharmaceuticals announced on Monday it will acquire bankrupt genomics firm 23andMe for $256 million through a bankruptcy auction, Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies. 1bn deal that marks the biggest healthcare equity Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4. TARRYTOWN, N. Sanofi registered sales of $129 million for the drug, up 91% from the . Explore Regeneron’s pipeline of investigational medicines advancing through clinical trials for a range of serious diseases. K. Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. 12, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. Regeneron (REGN) on Wednesday agreed to acquire Decibel Therapeutics (DBTX), a micro-cap biotech focused on gene therapies for $4. joc6s, iif3tr, vz18y, r85sqg, ar33j, qgbne, ndhd6j, kqnf, 8p9cz, wrlfa,